Guidelines

ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers

E. Tacconelli 1,2,*, F. Maizzaferri 2, A.M. de Smet 3, D. Bragantini 2, P. Eggimann 4, B.D. Huttner 5,6, E.J. Kuijper 7, J.-C. Lucet 8,9, N.T. Mutters 10,11, M. Sanguinetti 12, M.J. Schwaber 13,14, M. Souli 15,16, J. Torre-Cisneros 17, J.R. Price 18, J. Rodríguez-Baño 19

1) Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Germany
2) Infectious Diseases Section, Department of Diagnostic and Public Health, University of Verona, Verona, Italy
3) University of Groningen, University Medical Centre Groningen, Department of Critical Care, Groningen, the Netherlands
4) Adult Critical Care Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
5) Division of Infectious Diseases and Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland
6) Faculty of Medicine, University of Geneva, Geneva, Switzerland
7) Department of Medical Microbiology, Leiden University Medical Centre, Leiden, the Netherlands
8) Infection Control Unit, Bichat-Claude Bernard Hospital, AP-HP, Paris, France
9) IAME, UMR 1137, DeSCID team, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
10) European Committee on Infection Control (EUCIC), Basel, Switzerland
11) Institute for Infection Prevention and Hospital Epidemiology, Medical Centre, University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
12) Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Istituto di Microbiologia, Rome, Italy
13) National Centre for Infection Control, Israel Ministry of Health, Israel
14) Sackler Faculty of Medicine, Tel Aviv University, Israel
15) Duke Clinical Research Institute, Duke University, Durham, NC, USA
16) Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
17) Infectious Diseases Service, Reina Sofia University Hospital, Maimónides Institute for Biomedical Research (IMIBIC), Department of Medicine, University of Córdoba, Córdoba, Spain
18) Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, UK
19) Division of Infectious Diseases, Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena / Department of Medicine, University of Seville / Biomedicine Institute of Seville (IBIS), Seville, Spain

A R T I C L E  I N F O

Article history:
Received 30 October 2018
Received in revised form 8 January 2019
Accepted 12 January 2019
Available online 29 January 2019

Editor: L. Leibovici

Keywords:
Acinetobacter
Carbapenemase
Decolonization
Enterobacteriaceae
Extended-spectrum β-lactamase
Guideline
Multidrug-resistant Gram-negative
Pseudomonas
Stenotrophomonas

A B S T R A C T

Scope: The aim of these guidelines is to provide recommendations for decolonizing regimens targeting multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings.

Methods: These evidence-based guidelines were produced after a systematic review of published studies on decolonization interventions targeting the following MDR-GNB: third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE), aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginosa (XDRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), cotrimoxazole-resistant Stenotrophomonas maltophilia (CRSM), colistin-resistant Gram-negative organisms (CoRGNB), and pan-drug-resistant Gram-negative organisms (PDRGNB). The recommendations are grouped by MDR-GNB species. Faecal microbiota transplantation has been discussed separately. Four types of outcomes were evaluated for each target MDR-GNB:(a) microbiological outcomes (carriage and eradication rates) at treatment end and at specific post-treatment time-points; (b) clinical outcomes (attributable and all-cause mortality and infection incidence) at the same time-points and length of hospital stay; (c) epidemiological outcomes (acquisition incidence, transmission and outbreaks); and (d) adverse events of decolonization (including resistance development). The level of evidence for and strength of each recommendation were defined according to the GRADE approach. Consensus of a multidisciplinary expert panel was reached through a nominal-group technique for the final list of recommendations.

* Corresponding author. E. Tacconelli, Infectious Diseases Section, Department of Diagnostic and Public Health, Policlinico “G.B. Rossi”, P.le L.A. Scuro 10, 37134, Verona, Italy.

E-mail address: evelina.tacconelli@univr.it (E. Tacconelli).

https://doi.org/10.1016/j.cmi.2019.01.005
1198-743X/© 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
**Introduction**

Multidrug-resistant Gram-negative bacteria (MDR-GNB), including third-generation cephalosporin-resistant *Enterobacteriaceae* (3GCephRE), carbapenem-resistant *Enterobacteriaceae* (CRE), *Acinetobacter baumannii* and *Pseudomonas aeruginosa*, are a critical priority for new antibiotic research and development according to the World Health Organization (WHO) [1]. One of the criteria weighed by WHO experts for prioritization of antibiotic-resistant bacteria was the availability of infection-control measures to reduce the spread of infection in community and healthcare settings. The most important criteria for prioritizing MDR-GNB were not only an empty pipeline and high attributable mortality in severe infections but also the dearth of effective infection control measures against these pathogens [2–5].

Decolonization has been an effective tool for reduction of morbidity and mortality from infections due to methicillin-resistant *Staphylococcus aureus* (MRSA) [6]. The assumption underlying decolonization in individuals colonized by MRSA is that colonization increases the subsequent infection risk. A systematic review of the link between colonization and subsequent MRSA infection that included ten observational studies and 1170 patients showed a four-fold increase in infection risk associated with colonization [6]. Previous studies showed that colonization with MDR-GNB increases the risk of infections [7–16]. A prospective observational study in 497 haematological patients identified previous colonization with extended-spectrum β-lactamase-producing *Enterobacteriaceae* (ESBL-E) as the most important risk factor for ESBL-E bloodstream infections [7]. Previous colonization with MDR-GNB also increases infection risk in transplant and intensive care unit (ICU) patients and those undergoing major abdominal surgery [8–16]. Several factors have been associated with carriage phenotype: species and susceptibility pattern [17], host features, antibiotic exposure duration and type, and the extent of contact with healthcare environments [18–22].

The most extensive experience in MDR-GNB decolonization is with selective digestive decontamination (SDD) in ICU patients, but studies have shown conflicting results [12,13,23–26]. In randomized controlled trials (RCTs) performed in ICUs with low MDR-GNB endemicity, SDD significantly reduced infections and mortality with limited impact on new resistance selection [26–31]. Recently a study performed in a high-endemicity ICU in Spain over 4 years showed that SDD reduced MDR-GNB infections with a non-significant increase in resistance to decolonizing agents [32]. Major limitations of these studies are heterogeneity in patient case mix, ward colonization pressure, and agents combined in the decolonization protocols.

The most recently developed guidelines on prevention of CRE spread in hospitalized patients, evaluating studies up to 2014, do not advise for or against decolonization because of a very low level of evidence [2–4]. The objective of these guidelines is to provide evidence-based recommendations for decolonization of MDR-GNB carriers, irrespective of age, co-morbidities and setting. Specifically, we address the following questions:

(a) What decolonization regimens have been evaluated for patients colonized with the target MDR-GNB?

(b) Do we recommend decolonization for patients colonized with the target MDR-GNB?

(c) What is the regimen of choice for patients colonized with the target MDR-GNB?

Expected users in hospital and community healthcare settings include infection control specialists, healthcare providers (clinical medical, nursing and paramedical staff) and policy-makers.

**Methods**

These guidelines were developed by a multidisciplinary group of experts, selected by the European Committee of Infection Control (EUCIC) according to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommendations for developing guidance documents. This expert panel reviewed the articles and discussed evidence-based tables, evidence certainty classification, and recommendation strength in two meetings at ECCMID 2017 and 2018, and by teleconference. Consensus of panel members for the final list of recommendations was reached through a nominal-group technique.

**Literature search and data extraction**

We began the guidelines development process with a systematic review of the published literature. The review protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (https://doi.org/10.15124/CRD42017082729) and is available in full on the PROSPERO website (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=82729). The protocol followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [33]. We included all studies evaluating any decolonization regimen targeting patients colonized with MDR-GNB. Articles were identified through computerized literature searches using PubMed, the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials and Web of Science. The search was restricted to full-text articles published in English without restriction of publication year. A combination of Medical Subject Headings and equivalent terms was used in the search strategy (see Supplementary material, Appendix S1). Literature searches for each target organism were performed between 9 and 16 August 2017. Two independent reviewers performed a two-stage selection process. First, abstracts were screened against eligibility criteria and duplicate and irrelevant documents were excluded. We excluded studies involving universal decolonization (decolonization of all carriers, irrespective of age, co-morbidities and setting. Specifically, we address the following questions:

(a) What decolonization regimens have been evaluated for patients colonized with the target MDR-GNB?

(b) Do we recommend decolonization for patients colonized with the target MDR-GNB?

(c) What is the regimen of choice for patients colonized with the target MDR-GNB?

Expected users in hospital and community healthcare settings include infection control specialists, healthcare providers (clinical medical, nursing and paramedical staff) and policy-makers.
patients without previous screening), preoperative surgical prophylaxis, environmental decolonization, and in vitro and animal studies. Next, full-text articles were assessed, study data (design, population, target bacteria, intervention, comparison, treatment duration and outcomes) were extracted from eligible articles, and references were screened on title and abstract for further inclusion. At both stages each article was reviewed by two reviewers, and any discrepancies were resolved through discussion with a third reviewer (see flow charts in Supplementary material, Appendix S2).

A population/participant, intervention, comparator/control, outcome, known as PICO, framework was developed. Population: any patient of any age in any community or healthcare setting with any screening sample yielding one of the following MDR-GNB were included: 3GCephRE, CRE, aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant *Pseudomonas aeruginosa* (susceptibility maintained to up to two antibiotic classes: aminoglycosides, anti-pseudomonal carbapenem, antipseudomonal cephalexin, antipseudomonal fluoroquinolone, antipseudomonal penicillin + β-lactamase inhibitor, monobactam, phosphonic acid, polymyxin [34]), carbapenem-resistant *Acinetobacter baumannii* (CRAB), co-trimoxazole-resistant *Stenotrophomonas maltophilia*, colistin-resistant Gram-negative organisms, pan-drug-resistant (non-susceptible to all tested agents) Gram-negative organisms [34]. Intervention: decolonization therapy, defined as any measure that leads to loss of detectable MDR-GNB carriage at any site. Decolonizing regimens included topical agents, systemic therapy, antibiotic inhaled therapy, natural compounds, bacteriophage therapy, alternative treatments, and novel regimens undergoing trials. Controls: patients receiving no intervention (spontaneous decolonization) or a second decolonization measure were included. Outcomes: four outcome types—microbiological, clinical, epidemiological and adverse events—were evaluated for each target organism. The microbiological outcomes of carriage rate or eradication rate were assessed at different time-points (at treatment end and at 7 days, 1 month, 6 months and 1 year after treatment). Clinical outcomes included attributable and all-cause mortality and infection incidence at the same time-points, and length of hospital stay. Epidemiological outcomes included acquisition incidence, transmission, and outbreaks in hospitals, healthcare settings or the community. Assessment of decolonization adverse events included the investigation of resistance development. Because of the expected paucity of RCTs and non-randomized controlled trials, uncontrolled studies were also reviewed.

**Quality assessment**

The quality assessment was performed using the Effective Practice and Organization of Care guidelines for RCTs [35] and the Newcastle–Ottawa Scale for non-randomized controlled trials [36]. Each article was assessed by two reviewers, and discrepancies were resolved by a third reviewer. Evidence certainty of controlled studies was classified as high, moderate, low or very low, and recommendation strength was classified as strong or conditional according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [37]. The panel also assessed recommendations for research and possible conditional use in restricted trials and good practice points. The Supplementary material (Appendix S2) gives a detailed description of the GRADE approach, grades of evidence and determinants of quality.

**Results and recommendations**

The guidelines are organized by target organism. Each section reports the main characteristics of controlled studies, a summary of the evidence, and a recommendation graded according to the available evidence. Flow charts of assessed studies are included in the Supplementary material (Appendix S2). No articles were found for extremely drug-resistant *Pseudomonas aeruginosa*, co-trimoxazole-resistant *Stenotrophomonas maltophilia*, colistin-resistant Gram-negative organisms or pan-drug-resistant Gram-negative organisms. Twelve studies were included for 3GCephRE, 18 for CRE, six for CRAB, one for FQRE and one for AGRE. Of these studies, two 3GCephRE studies and seven CRE studies focused on faecal microbiota transplantation (FMT) are discussed separately at the end of this section. Tables 1–3 provide details of study designs and results.

**Third-generation cephalosporin-resistant Enterobacteriaceae**

**Study characteristics**

The ten studies were performed in Europe (nine studies) and the USA (one study): two RCTs [38,39], two prospective cohort studies [40,41], one uncontrolled nested post hoc analysis of a cluster-randomized study with additional hospital data [42], and five case series without comparators [43–47]. Only one study had a multicentre design [42]. Two studies evaluated hospital patients [38,39]; five evaluated ICU patients [41–43,45,47]; one evaluated liver transplanted patients [46]; two studied outpatients [39,44], and two studies were conducted in paediatric wards [43,45]. Four studies were performed during a 3GCephRE outbreak [41,43,46,47], three studies were performed in healthcare centres reporting endemic 3GCephRE [40,44,45], and three studies did not specify local epidemiology [38–40]. All studies performed rectal screening [38–47], four included urine cultures [38,39,41,45], and two included respiratory tract cultures [43,45].

Huttner et al. conducted an RCT to assess the efficacy of oral non-absorbable antibiotics on rectal ESBL-E carriage in hospital patients [38]. Fifty-eight patients were allocated to either placebo or oral colistin sulphate (50 mg (salt) four times daily) and neomycin sulphate (250 mg (salt) four times daily) for 10 days (plus nitrofurantoin for 5 days in the event of urine detection) [38]. Jonsson et al. assessed the role of anti-ESBL immunoglobulin Y chicken antibodies in ESBL-E faecal carriage eradication, randomizing 24 outpatients to either active treatment or placebo [39]. The RCT was discontinued before completion because of high drop-out. In an 8-year prospective cohort study, Buehlmann et al. enrolled 35 asymptomatic ESBL-E carriers and treated with chlorhexidine mouth rinse for 4 days for throat colonization, oral paromomycin for 4 days for rectal colonization, or oral nitrofurantoin or fosfomycin (single dose) or ciprofloxacin or cotrimoxazole for 5 days for urinary colonization [40]. The course was repeated in patients with persistent ESBL-E carriage. Decré et al. performed a prospective cohort trial of 404 patients colonized or infected with ESBL-producing *Klebsiella pneumoniae* and compared universal with target SDD using oral erythromycin (1 g twice daily) and colistin sulphate (6 million units twice daily) [41]. Decolonization regimens in the six uncontrolled studies differed widely: the most common agent was oral colistin alone [44] or combined with either oral aminoglycosides (neomycin, amikacin, or tobramycin) [42,43,45,47], erythromycin [47], rifaximin [44], or norfloxacin [46]. Treatment duration, when reported, ranged from 5 to 28 days. Oostdijk et al. conducted a nested post hoc analysis without comparator of a cluster-randomized multicentre trial in 13 Dutch ICUs. Fifty patients received oropharyngeal application of a paste containing colistin, tobramycin and amphotericin B, each at a concentration of 2%, and a 10-mL suspension containing 100 mg of colistin, 80 mg of tobramycin, and 500 mg of amphotericin B via a nasogastric tube. Topical antibiotics were applied four times daily until discharge from ICU. In addition, intravenous cefotaxime (1000 mg, every 6 h) was administered for the first 4 days. Rectal carriage of 3GCephRE and AGRE was determined at admission and twice weekly during the ICU stay [42].
Table 1
Characteristics of 27 included studies (sorted by study design)

<table>
<thead>
<tr>
<th>Author, year of publication [ref.]</th>
<th>Study design</th>
<th>Population</th>
<th>Target bacteria</th>
<th>Intervention</th>
<th>Comparison</th>
<th>Treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saidel-Odes, 2012 [51]</td>
<td>RCT</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Colistin (1 MIU) qid + gentamicin (80 mg) qid</td>
<td>Placebo</td>
<td>7 days</td>
</tr>
<tr>
<td>Nouvenne, 2015 [52]</td>
<td>RCT</td>
<td>Mixed population</td>
<td>CRE</td>
<td>High-dose probiotics + psyllium</td>
<td>Standard care</td>
<td>14 days</td>
</tr>
<tr>
<td>Huttner, 2013 [38]</td>
<td>RCT</td>
<td>Mixed population</td>
<td>ESBL-producer</td>
<td>Colistin sulphate (1.26 MIU) qid + neomycin sulphate (80 mg) qid</td>
<td>Placebo</td>
<td>10 days</td>
</tr>
<tr>
<td>Jonsson, 2015 [39]</td>
<td>RCT</td>
<td>Mixed population</td>
<td>ESBL-producer</td>
<td>Probiotic strain E. coli Nissle 1917 (5 x 10¹⁰ bacteria daily, twice daily)</td>
<td>Placebo</td>
<td>21 days</td>
</tr>
<tr>
<td>Tannock, 2011 [64]</td>
<td>RCT</td>
<td>Long-term care facility residents</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid or colistin (2 MIU) qid or gentamicin + colistin (150 mg) qid + tobramycin (80 mg) qid</td>
<td>Spontaneous decolonization</td>
<td>Up to eradication (maximum, 60 days)</td>
</tr>
<tr>
<td>Oren, 2013 [53]</td>
<td>Semi-randomized trial</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid or streptomycin (80 mg) tid + neomycin (40 mg) tid</td>
<td>Interrupted decolonization</td>
<td>4–5 days; repeated courses until achievement of eradication</td>
</tr>
<tr>
<td>Buehmann, 2011 [40]</td>
<td>Prospective cohort</td>
<td>Mixed population</td>
<td>3GcephRE ESBL producer</td>
<td>Colistin-resistant CRE</td>
<td>Standard care</td>
<td>14 days</td>
</tr>
<tr>
<td>Decré, 1998 [41]</td>
<td>Prospective cohort</td>
<td>ICU</td>
<td>3GcephRE ESBL producer</td>
<td>Erythromycin (1 g) bid + polymixin E (6 MIU) bid</td>
<td>Universal decolonization</td>
<td>Not reported</td>
</tr>
<tr>
<td>Borner, 2007 [65]</td>
<td>Prospective cohort</td>
<td>ICU</td>
<td>CRAB</td>
<td>Topical 4% chlorhexidine, one full body wash daily</td>
<td>Standard care</td>
<td>Not reported</td>
</tr>
<tr>
<td>Machuca, 2016 [55]</td>
<td>Retrospective cohort</td>
<td>Mixed population</td>
<td>3GcephRE ESBL producer</td>
<td>Colistin (solution 1%, 1 mL/kg) qid + tobramycin (80 mg) qid</td>
<td>Spontaneous decolonization</td>
<td>7 days</td>
</tr>
<tr>
<td>Lubbert, 2013 [34]</td>
<td>Retrospective cohort</td>
<td>ICU</td>
<td>CRE</td>
<td>Gentamicin sulphate (80 mg) qid + tobramycin (80 mg) qid</td>
<td>Standard care</td>
<td>Not reported</td>
</tr>
<tr>
<td>Agusti, 2002 [66]</td>
<td>Case–control</td>
<td>ICU</td>
<td>CRAB</td>
<td>Colistin sulphate (1 MIU) qid + gentamicin (150 mg) qid + tobramycin (80 mg) qid</td>
<td>Variable (mean, 35.8 days)</td>
<td>Not reported</td>
</tr>
<tr>
<td>Chen, 2014 [67]</td>
<td>Case–control</td>
<td>Mixed population</td>
<td>CRAB</td>
<td>Inhaled colistin (2 MIU/160 mg) bid</td>
<td>Standard care</td>
<td>Variable (10.9 ± 3.6 days)</td>
</tr>
<tr>
<td>Kuo, 2012 [68]</td>
<td>Case–control</td>
<td>Mixed population</td>
<td>CRAB</td>
<td>Inhaled colistin (2 MIU/160 mg) bid</td>
<td>Standard care</td>
<td>Up to ICU discharge</td>
</tr>
<tr>
<td>Oostdijk, 2012 [42]</td>
<td>Nested post hoc analysis</td>
<td>ICU</td>
<td>3GcephRE, AGRE</td>
<td>Colistin (2 MIU) qid + tobramycin (80 mg) qid + cefotaxime (1 g) qid</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Gutierrez-Urbon, 2015 [43]</td>
<td>Case series</td>
<td>Paediatric ICU</td>
<td>3GcephRE ESBL producer</td>
<td>Colistin (solution 1%, 1 mL/kg) qid + amikacin (solution 3.2%, 1 mL/kg) qid</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Rieg, 2015 [44]</td>
<td>Case series</td>
<td>Mixed population</td>
<td>3GcephRE ESBL producer</td>
<td>Colistin standard dose (1 MIU) or high dose (2 MIU) qid or rifaximin</td>
<td>NA</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Abecasis, 2011 [45]</td>
<td>Case series</td>
<td>Paediatric ICU</td>
<td>3GcephRE ESBL producer</td>
<td>Colistin + tobramycin + cefotaxime (doses not specified)</td>
<td>NA</td>
<td>Not reported</td>
</tr>
<tr>
<td>Paterson, 2001 [46]</td>
<td>Case series</td>
<td>SOT</td>
<td>3GcephRE ESBL producer</td>
<td>Norfloxacin (400 mg) bid</td>
<td>NA</td>
<td>5 days</td>
</tr>
<tr>
<td>Troché, 2005 [47]</td>
<td>Case series</td>
<td>ICU</td>
<td>3GcephRE ESBL producer</td>
<td>2 among colistin sulphate (1.5 MIU) qid, neomycin (500 mg) qid or erythromycin (500 mg) qid</td>
<td>NA</td>
<td>Not reported</td>
</tr>
<tr>
<td>De Rosa, 2016 [56]</td>
<td>Case series</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid</td>
<td>NA</td>
<td>Variable (mean, 5 days)</td>
</tr>
<tr>
<td>Tascini, 2014 [59]</td>
<td>Case series</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid</td>
<td>NA</td>
<td>&gt;7 days, variable (mean, 16 days)</td>
</tr>
<tr>
<td>Zuckerman, 2011 [57]</td>
<td>Case series</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid</td>
<td>NA</td>
<td>Up to eradication (mean, 27 days; range, 7–90 days)</td>
</tr>
<tr>
<td>Lambelet, 2017 [58]</td>
<td>Case series</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid</td>
<td>NA</td>
<td>Up to eradication (range, 7–25 days)</td>
</tr>
<tr>
<td>Gray, 2016 [69]</td>
<td>Case series</td>
<td>Mixed population</td>
<td>CRAB</td>
<td>Chlorhexidine gluconate-impregnated wipes 25 daily</td>
<td>NA</td>
<td>Not reported</td>
</tr>
<tr>
<td>Hsieh, 2014 [70]</td>
<td>Case series</td>
<td>Mixed population</td>
<td>CRAB</td>
<td>Colistin sulphate (2 MIU) bid</td>
<td>NA</td>
<td>Variable (range, 11–13.5 days)</td>
</tr>
<tr>
<td>Kronman, 2014 [61]</td>
<td>Case report</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin + colistin (doses not specified)</td>
<td>NA</td>
<td>10 days</td>
</tr>
<tr>
<td>Brink, 2013 [60]</td>
<td>Case report</td>
<td>CRE</td>
<td>3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae</td>
<td>Colistin + tobramycin (doses not specified)</td>
<td>NA</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

Abbreviations: AGRE, aminoglycoside-resistant Enterobacteriaceae; bid, twice daily; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase; FQRE, fluoroquinolone-resistant Enterobacteriaceae; ICU, intensive care unit; IgG, immunoglobulin G; NA, not applicable; qid, four times daily; RCT, randomized controlled trial; SOT, solid organ transplant; 3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae; tid, thrice daily.
Clinical outcomes

Two case series [43,45] and the nested post hoc analysis [42] included clinical outcomes (all-cause mortality at treatment end or length of stay)—Abecasis et al. reported a 20.5% (8/39) mortality rate [45] and Gutierrez-Urbon et al. reported no deaths [43]. Oostdijk et al. observed a median ICU stay of 12 days (range 3–77; interquartile range (IQR), 10) for 3GcephRE-colonized patients and 13 days (range 3–77; IQR, 11) for decolonized patients [42].

Microbiological outcomes

One RCT [38], one prospective cohort study [40] and all studies without comparator [42–47] included microbiological outcomes (carriage rate or eradication rate). Huttner et al. observed a significantly lower rectal carriage rate in the treatment group than in the placebo group at treatment end (32.0% (8/25) versus 76.9% (20/26); p 0.001), but the effect was lost at 7 days post-treatment (66.7% (18/27) versus 68% (17/25); p 0.92) and at 28 days post-treatment (51.9% (14/27) versus 37% (10/27); p 0.28) [38]. Buehlmann et al. showed that repeated decolonization significantly improved eradication rate at treatment end (88.9% (16/18) versus 41.1% (7/17); p 0.007) [40]. The studies without comparator reported decolonization rates at treatment end ranging from no effect to 100% [42–47].

Epidemiological outcomes

One prospective cohort study [41] evaluated the impact of decolonization regimen on epidemiological outcomes (incidence of acquired colonization and acquired infections). No significant difference from the historical control group was observed in the incidence of acquired 3GcephRE colonization in the digestive tract (10% versus 9.1%) or in the incidence of acquired infections (7.5% versus 3.6%).

Adverse events

Resistance development was assessed in one RCT and one uncontrolled study [38,42]. Huttner et al. observed no statistically significant changes in the colistin or neomycin MICs between baseline and final ESBL-E isolates in the treatment group [38]. Oostdijk et al. found no association with increased resistance over time when eradication failed [42]. Adverse events were evaluated in two RCTs [38,39] and one study without comparator [43]. In the Huttner et al. trial, 7/27 (25.9%) patients in the treatment group versus 2/29 (6.9%) patients in the placebo group (p 0.05) experienced liquid stool during follow up [38], whereas in the Jonsson study the proportion of participants who reported various adverse events was similar between the treatment and the placebo groups (58% versus 42%) [39].

Other relevant outcomes

A significantly lower rectal carriage rate was observed by Huttner et al. on day 6 of treatment (9/26 (34.6%) versus 19/22 (86.3%); p < 0.001) [38].

Evidence evaluation

Evidence was of moderate [38] and very low [40] certainty for microbiological eradication at treatment end, low for microbiological eradication at 7 days and 28 days post-treatment [38] and for resistance development [38,39], and very low for adverse events [38,39].

Recommendation

The panel does not recommend routine decolonization of 3GcephRE carriers.

Grading: conditional recommendation against the intervention.

Research and possibly conditional use in restricted trials

On the basis of the limited evidence of temporary effectiveness of decolonization [38,40] and the increased risk of developing ESBL-E bloodstream infections in neutropenic colonized patients [7,48,49], the panel suggests designing clinical trials of decolonization with oral colistin sulphate (50 mg (salt) four times daily) and neomycin sulphate (250 mg (salt) four times daily) to temporarily suppress 3GcephRE carriage in patients with severe neutropenia (absolute neutrophil count <500 µL). These trials should include careful monitoring for development of resistance to neomycin or colistin during decolonization using stool cultures and antimicrobial susceptibility results according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints [50].

Carbapenem-resistant Enterobacteriaceae

Study characteristics

The 11 studies were performed in Europe (6), Israel (3), South Africa (1) and the USA (1): two RCTs [51,52], one semi-randomized control trial [53], two retrospective cohort studies [54,55], and six case series and case reports without comparators [56–61]. Two studies had a multicentre design [55,59]. Six studies evaluated hospital inpatients [51–53,55,59,60], one assessed ICU patients [54], and four evaluated haematological patients [56,57,59,61]. Four studies were performed during a CRE outbreak [54,55,57,60]. Seven studies did not specify local epidemiology [51,53,55,56,58,59,61]. Rectal carriage testing was performed in all studies, and urinary carriage and respiratory tract colonization were assessed in one study each [51,54].

Saidel-Odes et al. conducted an RCT to test the efficacy of intestinal decontamination on CRE carriage. Forty patients were randomized to receive either placebo or colistin (1 MU four times daily) and gentamicin sulphate (80 mg four times daily) for 7 days [51]. Nouvenne et al. performed an RCT in 32 patients assessing the role of high-dose probiotics in CRE faecal carriage eradication. The patients were randomly assigned to either high-dose probiotics and psyllium for 14 days or standard care [52]. Oren et al. evaluated 50 patients treated with one of three regimens: colistin sulphate (2 MU four times daily), gentamicin sulphate (80 mg four times daily), or both [53]. The patients were assigned to antibiotic regimens either according to susceptibility or randomly (for carriers of strains susceptible to both colistin and gentamicin). Patients undergoing treatment were compared with controls (102 patients) for eradication and clinical outcomes. Machuca et al. analysed a retrospective cohort of 77 patients using two regimens: gentamicin solution (80 mg four times daily) or streptomycin sulphate (80 mg three times daily) and neomycin (40 mg three times daily) for 14 days [55], Lubbert et al. analysed a retrospective cohort of 16 ICU patients treated for 7 days with colistin sulphate (1 MU four times daily) and gentamicin sulphate (80 mg four times daily) [54].

Clinical outcomes

All controlled studies [51–55] and four studies without comparator [56–60] included clinical outcomes (all-cause and attributable mortality, CRE-related infection incidence or length of hospital stay). Machuca et al. reported a significant reduction in all-cause mortality associated with the use of decolonization therapy at 6 months after treatment end (25% versus 54%; hazard ratio (HR) 0.18; 95% CI 0.06–0.55) [55]. Oren et al. observed a reduction in all-cause mortality without impact on attributable mortality during the follow-up period (timing not specified) (22% (11/50) versus 53% (54/102); p < 0.001) [53]. Nouvenne et al. and Lubbert et al. did not
find any significant effect of decolonization treatment on mortality during hospitalization [52,54].

Machuca et al. reported a significant reduction in the CRE-related infection incidence at 6 months follow up (4.5% (2/44) versus 39.4% (13/33); p < 0.001) [55]. Univariate analysis demonstrated a lower risk of carbapenemase-producing K. pneumoniae infections in the follow-up period associated with decolonization (HR 0.14; 95% CI 0.02–0.83). Only gentamicin was significantly associated with infection rate reduction in the analysis stratified by treatment (crude HR 0.86; 95% CI 0.008–0.94). Two studies analysing the effect of decolonization on length of hospital stay found no difference between treated and untreated patients [51,54].

**Microbiological outcomes**

All controlled studies [51–55] and all studies without comparator [56–61] included microbiological outcomes (carriage rate or eradication rate). In the RCT by Saidel-Odes et al., significant carriage rate reduction was observed 7 days post-treatment (38.8% versus 83.9%; OR 0.13; 95% CI 0.02–0.74; p < 0.0016), but the effect was lost at 28 days, resulting in a non-significant difference between the two groups (41.5% versus 66.7%) [51]. In the RCT by Nouvenne et al., significant reduction in carriage rate during hospitalization was associated with administration of high-dose probiotics (p 0.009) [52]. In the semi-randomized trial by Oren et al., the eradication rate during follow up was significantly higher in the intervention group (56% (22/50)) versus 7% (7/102); p < 0.001) [53]. The retrospective cohort study by Machuca et al. found a significant difference in decolonization rate between the control and treated groups (51.1% versus 9.1%; p < 0.001) at 180 days post-treatment (HR 4.06; 95% CI 1.06–15.6) [55]. When stratified by treatment regimen, gentamicin was associated with a significantly higher microbiological success rate (HR 5.67; 95% CI 1.33–24.1). The other regimen (streptomycin and neomycin combination) showed no significant association. The retrospective cohort study by Lubbert et al. showed no significant difference in the decolonization rate between the two groups [54].

### Table 2

**Microbiological outcomes**

<table>
<thead>
<tr>
<th>Author, year of publication [ref.]</th>
<th>Target bacteria</th>
<th>Sample size</th>
<th>Time-point</th>
<th>Eradication rate</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saidel-Odes, 2012 [51]</td>
<td>CRE</td>
<td>Intervention 20; control 20</td>
<td>7 days after EoT</td>
<td>OR, 0.13</td>
<td>0.02–0.74</td>
<td>0.0016</td>
</tr>
<tr>
<td>Nouvenne, 2015 [52]</td>
<td>CRE</td>
<td>Intervention 18; control 14</td>
<td>28 days after EoT</td>
<td>58.3% vs. 33.3%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Hutner, 2013 [38]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 27; control 27</td>
<td>EoT</td>
<td>NA</td>
<td>0.0094</td>
<td></td>
</tr>
<tr>
<td>Tannock, 2011 [64]</td>
<td>FQRE</td>
<td>Intervention 36; control 33</td>
<td>28 days after EoT</td>
<td>0.18–1.62</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Oren, 2013 [53]</td>
<td>CRE</td>
<td>Intervention 50; control 102</td>
<td>5 weeks after EoT</td>
<td>23% vs. 42%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Buehnemann, 2011 [40]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 18; control 17</td>
<td>EoT</td>
<td>NA</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Machuca, 2016 [55]</td>
<td>CRE</td>
<td>Intervention 44; control 33</td>
<td>6 months after EoT</td>
<td>OR, 4.06</td>
<td>1.06–15.6</td>
<td>0.04</td>
</tr>
<tr>
<td>Lubbert, 2013 [54]</td>
<td>CRE</td>
<td>Intervention 16; control 76</td>
<td>NA</td>
<td>57% vs. 83%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Agusti, 2002 [66]</td>
<td>CRAB</td>
<td>Intervention 33; control 21</td>
<td>EoT</td>
<td>52% vs. 9%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Chen, 2014 [67]</td>
<td>CRAB</td>
<td>Intervention 81; control 54</td>
<td>14 days after EoT</td>
<td>54% vs. 30%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Kuo, 2012 [68]</td>
<td>AGRE</td>
<td>Intervention 39; control 39</td>
<td>28 days after EoT</td>
<td>85% vs. 10%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Oostdijk, 2012 [42]</td>
<td>3GCephRE</td>
<td>Intervention 77; control NA</td>
<td>14 days after EoT</td>
<td>Colistin SD 39%; colistin HD 25%; rifaximin 60%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Gutierrez-Urbon, 2015 [43]</td>
<td>3GCephRE</td>
<td>Intervention 6; control NA</td>
<td>EoT</td>
<td>73%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Rieg, 2015 [44]</td>
<td>3GCephRE</td>
<td>Intervention 45; control NA</td>
<td>14 days after EoT</td>
<td>Colistin SD 39%; colistin HD 25%; rifaximin 60%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Abecasis, 2011 [45]</td>
<td>3GCephRE</td>
<td>Intervention 39; control NA</td>
<td>EoT</td>
<td>77%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Paterson, 2001 [46]</td>
<td>3GCephRE</td>
<td>Intervention 9; control NA</td>
<td>EoT</td>
<td>100%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Troche, 2005 [47]</td>
<td>3GCephRE</td>
<td>Intervention 37; control NA</td>
<td>28 days after EoT</td>
<td>44%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>De Rosa, 2016 [56]</td>
<td>CRE</td>
<td>Intervention 8; control NA</td>
<td>14 days after EoT</td>
<td>52%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Tascini, 2014 [59]</td>
<td>CRE</td>
<td>Intervention 50; control NA</td>
<td>14 days after EoT</td>
<td>68%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Zuckerman, 2011 [57]</td>
<td>CRE</td>
<td>Intervention 15; control NA</td>
<td>14 days after EoT</td>
<td>66%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Lambelet, 2017 [58]</td>
<td>CRE</td>
<td>Intervention 14; control NA</td>
<td>14 days after EoT</td>
<td>71%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Hseih, 2014 [70]</td>
<td>CRAB</td>
<td>Intervention: - Colonized group 61</td>
<td>NA</td>
<td>72%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Kronman, 2014 [61]</td>
<td>CRE</td>
<td>Intervention 1; control NA</td>
<td>28 days after EoT</td>
<td>100%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Brink, 2013 [60]</td>
<td>CRE</td>
<td>Intervention 1; control NA</td>
<td>EoT</td>
<td>0%</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** aHR, adjust hazard ratio; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase; EoT, end of treatment; FQRE, fluoroquinolone-resistant Enterobacteriaceae; HD, high dose; NA, not applicable; NS, not significant; OR, odds ratio; SD, standard dose; 3GCephRE, third-generation cephalosporin-resistant Enterobacteriaceae.
### Table 3
Clinical outcomes

<table>
<thead>
<tr>
<th>Author, year of publication [ref.]</th>
<th>Target bacteria</th>
<th>Sample size</th>
<th>Clinical outcome</th>
<th>Time-point</th>
<th>Effect size</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noulvo, 2015 [52]</td>
<td>CRE</td>
<td>Intervention 18; control 14</td>
<td>All-cause mortality</td>
<td>NA</td>
<td>31% vs. 12%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Oren, 2013 [53]</td>
<td>CRE</td>
<td>Intervention 50; control 102</td>
<td>All-cause mortality</td>
<td>NA</td>
<td>22% vs. 53%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Machuca, 2016 [55]</td>
<td>Colistin-resistant CRE</td>
<td>Intervention 44; control 33</td>
<td>All-cause mortality</td>
<td>6 months after EoT</td>
<td>aHR, 0.18</td>
<td>0.06-0.55</td>
<td>0.003</td>
</tr>
<tr>
<td>Lubbert, 2013 [54]</td>
<td>CRE</td>
<td>Intervention 16; control 76</td>
<td>All-cause mortality</td>
<td>6 months after EoT</td>
<td>aHR, 0.14</td>
<td>0.02-0.84</td>
<td>0.03</td>
</tr>
<tr>
<td>Agusi, 2002 [66]</td>
<td>CRAB</td>
<td>Intervention 33; control 21</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>36% vs. 45%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Chen, 2014 [67]</td>
<td>CRAB</td>
<td>Intervention 81; control 54</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>14% vs. 16%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Kuo, 2012 [68]</td>
<td>CRAB</td>
<td>Intervention 39; control 39</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>9% vs. 10%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Gutierrez-Urbon, 2015 [43]</td>
<td>3GcephRE</td>
<td>Intervention 6; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>15% vs. 7%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Abecasis, 2011 [45]</td>
<td>3GcephRE</td>
<td>Intervention 39; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>20% vs. 31%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>De Rosa, 2016 [56]</td>
<td>CRE</td>
<td>Intervention 8; control NA</td>
<td>All-cause mortality</td>
<td>6 months after EoT</td>
<td>37%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Tascini, 2014 [59]</td>
<td>CRE</td>
<td>Intervention 50; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>36%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Zuckerman, 2011 [57]</td>
<td>CRE</td>
<td>Intervention 15; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>20%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lambi, 2017 [58]</td>
<td>CRE</td>
<td>Intervention 14; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>53%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Gray, 2016 [69]</td>
<td>CRAB</td>
<td>Intervention 29; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>7%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hseih, 2014 [70]</td>
<td>CRAB</td>
<td>Intervention</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>33%</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: aHR, adjust hazard ratio; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase; EoT, end of treatment; NA, not applicable; NS, not significant; 3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae.

### Epidemiological outcomes
None of the studies evaluated epidemiological outcome.

### Adverse events
Resistance development was assessed in one RCT [51], three controlled studies [53–55] and all studies without comparator [56–61]. Among controlled studies, an increase in secondary resistance to decolonizing agents was reported in three studies [53–55]. Machuca et al. found that a significantly higher proportion of patients undergoing decolonization had gentamicin-resistant isolates in follow-up cultures than those not treated (13% (6/44) versus 3% (1/33); p 0.008) [55]. In the Oren et al. and Lubbert et al. studies, 14% (7/50) and 28% (4/14) of patients, respectively, developed secondary resistance to decolonizing agents [53,54]. Saidel-Odes et al. did not observe increased resistance in their RCT [51]. None of the controlled studies reported a higher adverse event incidence in the intervention group.

### Evidence evaluation
Evidence was of low certainty for microbiological eradication at 1 week [51] and 6 months [55] post-treatment and CRE infection incidence at 6 months [55], and of very low certainty for microbiological eradication at 4 weeks [51] and all-cause mortality [55].

### Recommendation
The panel does not recommend routine decolonization of CRE.

Grading: conditional recommendation against the intervention.

### Research and possibly conditional use in restricted trials
On the basis of the limited evidence of increased risk of developing CRE infections in the colonized ICU population [12,13,62,63] and the results of the effectiveness of decolonization on CRE carriers [51,53], the panel suggests designing good-quality clinical studies to assess CRE infection risk in colonized haematological patients and solid organ transplant recipients. The panel further suggests using the results of these trials to design decolonization trials with oral colistin sulphate (50 mg (salt) four times daily) with or without gentamicin sulphate (80 mg (salt) four times daily) to temporarily suppress CRE carriage in high-risk patients. These trials should include careful monitoring of development of resistance to gentamicin and colistin during decolonization using stool cultures and antimicrobial susceptibility results according to the EUCAST clinical breakpoints [50].

### Fluoroquinolone-resistant Enterobacteriaceae

#### Study characteristics
Tannock et al. conducted a multicentre RCT in New Zealand to evaluate the efficacy of the probiotic strain Escherichia coli Nissle 1917 on FQRE colonization [64]. Sixty-nine elderly residents in long-term care facilities excreting norfloxacin-resistant E. coli were randomized to receive either probiotic (5 x 10^8 to 5 x 10^10 bacteria daily, one capsule twice daily) or placebo for 5 weeks. Rectal and urinary carriage testing were assessed in the trial.

#### Clinical outcomes
No clinical outcome was assessed.

#### Microbiological outcomes
No significant difference was found in decolonization rate between the control and treated groups at 5 weeks post-treatment.

#### Epidemiological outcomes
No epidemiological outcome was analysed.
Adverse events
No adverse event was evaluated.

Evidence evaluation
Evidence was of low certainty for microbiological eradication at 5 weeks post-treatment.

Recommendation
Evidence is insufficient to provide a recommendation for or against any intervention.

Aminoglycoside-resistant Enterobacteriaceae

Study characteristics
The Oostdijk et al. study [42] is described above in the 3GCephRE section.

Clinical outcomes
Median length of ICU stay was 11.5 days (range 4–82; IQR 9.5) for AGRE-colonized patients and 12 days (range, 4–82; IQR 8) for decolonized patients.

Microbiological outcomes
The eradication rate was 62% (31/50) after a median of 5.5 days (IQR 3–60 days) of decolonization.

Epidemiological outcomes
No epidemiological outcome was analysed.

Adverse events
No increased resistance overtime was seen when eradication failed.

Recommendation
Evidence is insufficient to provide a recommendation for or against any intervention.

Clinic outcomes
Three case–control studies [66–68], one prospective cohort study [65], and one uncontrolled study [70] assessed clinical outcomes (all-cause mortality and infection rate). No significant difference in all-cause mortality during ICU stay was observed after oral decolonization [66]. All-cause mortality was assessed in two case-control studies comparing inhaled colistin with standard care, and no significant differences in mortality was observed [67,68]. Only Borer et al. observed a significant reduction in CRAB bloodstream infections after the intervention (0.6% versus 4.65%; p < 0.001) [65].

Microbiological outcomes
Three studies evaluated eradication rate [66–68]. Persistent CRAB carriage 14 days after treatment was assessed in two controlled studies. Chen et al. observed 14-day eradication in 54.3% of patients receiving decolonization versus 29.6% of controls (p = 0.005), although a significant association was not observed for 28-day eradication rates (66.7% versus 51.9%; p = 0.084) [67]. Kuo et al. observed a significant 14-day eradication rate (84.6% versus 10.3%; p < 0.001) [68]. Agusti et al. found significant reduction in faecal (48% versus 91%; p = 0.001) and pharyngeal (38% versus 78%; p = 0.03) carriage at discharge in patients who received SDD compared with controls. SDD did not affect cutaneous carriage [66].

Epidemiological outcomes
No epidemiological outcome was analysed.

Adverse events
Kuo et al. assessed colistin resistance development, specifically changes in colistin MIC (one-fold to two-fold) between isolates cultured from the same patients. No significant difference between case and control groups was observed (8/28 (28.6%) versus 4/30 (13.3%); p = 0.15) [68].

Evidence evaluation
Evidence was of very low certainty for all the assessed outcomes.

Recommendation
Evidence is insufficient to provide a recommendation for or against any intervention.

Faecal microbiota transplantation
Faecal microbiota transplantation is the administration of thoroughly screened, healthy-donor stool into a patient’s gut, either into the colon (via enema or colonoscopy) or into the upper small intestine (via nasojejunal tube or swallowed capsules) [71]. The potential benefit of FMT as an MDR-GNB decolonization strategy has been tested in nine uncontrolled studies with a high level of heterogeneity [72–80].

A single-centre study by Bilinski et al. investigated the use of FMT for MDR-GNB eradication in patients with haematological disorders [72]. Twenty-five FMTs were performed in 20 patients with intestinal MDR-GNB colonization, mainly carbapenemase- or ESBL-producing Enterobacteriaceae. Complete decolonization was achieved in 60% (15/25) of the cases at 1 month and in 13/14 (93%) of cases at 6 months post-treatment. Antibiotic use within 7 days post-treatment hampered the effectiveness of the intervention.

Davido et al. reported the results of a series of eight FMTs, of which six were performed in patients colonized with carbapenemase-producing Enterobacteriaceae [73]. Eradication was obtained in two patients at 1 month post-treatment. No relapse of
colonization was detected through 3 months of follow up. Table 4 provides details of study design and results.

Recommendation
Evidence is insufficient to provide a recommendation for or against FMT. Further studies are warranted to evaluate the effectiveness, applicability, and safety of FMT to confirm its role in intestinal decolonization of MDR-GNB.

Limitations of the evidence and future research
Our systematic review has identified important gaps in the literature on targeted decolonization strategies in MDR-GNB carriers. Studies have been evaluated for only a few clinically relevant MDR-GNB in specific settings, and, of those assessed, data are insufficient to provide robust recommendations on decolonization. High heterogeneity was detected among studies and did not allow any meta-analytic approach but only a qualitative review. The panel identified the following major flaws in the evaluated evidence: inconsistent reporting, small sample size, key outcomes not assessed, inconsistent effectiveness definition, colistin susceptibility testing not in accordance with current recommendations, and wide heterogeneity between settings (outbreak, endemic), decolonization regimens and treatment duration. The assessment typically evaluated a single intervention although multiple infection control measures are often implemented together as a bundle in clinical practice.

Because of the lack of effective drugs for MDR-GNB, the development of novel decolonization strategies through well-designed in vitro and in vivo studies is urgently needed [81]. These strategies may include natural compounds (FMT, prebiotics, probiotics), alternative therapies (tea tree oil, photodynamic therapies, omigan tanthoxydim), and bacteriophage therapy. Well-designed multicentre RCTs are required to determine the impact of decolonization strategies on microbiological, epidemiological and clinical outcomes and development of resistance. Furthermore, the studies should evaluate the optimal dosing, duration, target populations and setting (endemic versus outbreak), and cost-effectiveness. Sequential interventions (e.g. oral SDD followed by FMT) should be explored. Evaluation of the efficacy of multimodal decolonization methods in stepped-wedge cluster RCTs should also be considered. Metagenomic studies assessing the effect of decolonizing agents on the microbiota composition and dynamics could provide valuable evidence for designing RCTs and drive choices of old and new drugs to be tested. Although it is understandable that research to date has focused on organisms with current significant clinical impact (3GCephRE, CRE, CRAB), we should not neglect other MDR-GNB (e.g. extremely drug-resistant Pseudomonas aeruginosa, pan-drug-resistant Gram-negative organisms) for which current experience is low but is likely to increase in the future.

Key points
- The panel does not recommend routine decolonization of MDR-GNB carriers.
- The effectiveness and long-term side effects of decolonization of 3GCephRE and CRE in high-risk populations (e.g. ICU, neutropenic and transplant populations) needs to be evaluated with RCTs with proper design and sample size calculation.

Transparency declaration
ET, FM, AMD, DB, BDH, EJK, JCL, NTM, MJS, Maria Souli, JTC, JRP declared no conflicts of interest. PE has witnessed advisory and consultancy roles at Abionic, 3M, Pfizer and received research support from 3M. Maurizio Sanguinetti received research support from Recordati, Pfizer and Menarini s.p.a. JRB participated in accredited educational activities supported by Merck through unrestricted grants and was coordinator of a drug-unrelated research project funded by AstraZeneca.

Funding
Evelina Tacconelli and the current expert group are responsible for updating these guidelines with a time frame of 2 years between publishing and commencing the next updating process. If high-quality evidence is published within the 2-year time frame, the group will analyse the data and report to the scientific community in a timely manner.

Acknowledgements

We thank Anne McDonough, a professional medical writer funded by ESCMID, for editorial assistance.

A preliminary version of these guidelines was presented at ECCMID 2018, 21–24 April 2018, Madrid, Spain.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2019.01.005.

References


[37] Gutierrez-Urbon JM, Feal-Cortizas B, Suarez-Lorenzo JM, et al. Failure of a 5 day course of selective digestive decontamination solution in rectal


